A Baltimore startup developing artificial organ technology has raised about $3 million in equity funding, according to U.S. Securities and Exchange Commission documents.
Medical device firm Breethe Inc. reported the round this month, which included 22 investors.
Emmes is proud to have advanced Glaucoma research w/ support from @NatEyeInstitute! Our 1st ophthalmic trial (published in @AmJOphthalmol) showed little visual field deterioration in pts w/ low intraocular pressure
The GammaPod ™ – a first-of-its kind stereotactic radiotherapy system to treat early stage breast cancer – has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), paving the way for the manufacturer to bring the system to market for the treatment of breast cancer patients.
MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases, announced today that it had entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to jointly discover and develop novel bispecific molecules to undisclosed targets. During the research term, both companies will leverage their respective platforms, including MacroGenics’ DART® platform and Roche’s CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate.
Currently, we depend upon the eyes, ears, and touch of medical staff to examine the human body and diagnose patients. Physicians must identify abnormalities of the skin, check for any bodily irregularities, examine complex MRIs, listen for arrhythmias, and inspect CT scans day in and day out. While all of these tasks seem routine, they actually test physicians’ knowledge about everything that could possibly be wrong with the human body.
2017 was an extraordinary year in the history of medicine. It was the year when scientists beat cancer, and U.S. regulators approved the first therapy to fix a faulty gene. It was also a year that kept us enthralled with a quickening drumbeat of breathtaking news detailing spectacular advances – trials seemingly curing patients of hemophilia A and sickle cell anemia, and breakthroughs raising similar hopes for Huntington’s disease, Lou Gehrig’s disease, and even HIV.
It’s hard to believe that the book has already closed on 2017. As we turn the calendar to 2018, I wanted to pause and share some highlights from MdBio’s monumental last twelve months. Partners, supporters and STEM advocates like you are instrumental to our success – thank you for all that you have done in support of MdBio and our programs.
The 4th annual Biotech and Money/Medtech and Money World Congress will offer insight into the investment landscape for biotech and medtech companies via a series of panel discussions with leading investors in the sector. Those attending the two-day event in London can hear from experienced investors about the current state of funding for life science companies at varying stages of development. This includes a focus on seed funding, with panel discussions on ‘Seed funding for biotech development’ and ‘PanEuropean medtech seed funding’.
Alexandria Real Estate recently completed a large building on the west side of Lake Union and now it’s starting to plan one on Eastlake.
Blockchain startup Akiri has received $10 million in Series A funding to develop a distributed ledger platform for health data.
